The 2nd US Circuit Court of Appeals in Manhattan overturned a $21 million judgment in favor of Tiffany & Co's against Costco Wholesale Corp over the latter's sale of diamond engagement rings bearing the "Tiffany" name.
In a 3-0 decision, the court agreed with Costco's argument that its use of the name "Tiffany" was unlikely to confuse customers. It also ruled that Costco may describe the style of its engagement rings even if confusion were likely.
Tiffany had sued Costco for trademark infringement in 2013 after an estimated 3,349 customers bought Tiffany-set rings at Costco during Valentine's Day season that year.
Costco countered that "Tiffany" had become a generic term, and claimed it had removed the "Tiffany" signage within a week after being contacted by that company.
The $21 million awarded to Tiffany, one of the world's most famous luxury retailers, included $11.1 million for lost profit due to the alleged infringement, $8.25 million in punitive damages, and interest.


Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal
Google Secures Pentagon AI Deal for Classified Projects
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 



